Magellan Health, Inc. (NASDAQ:MGLN) went higher by +1.12% to close at $ 72.40. The company exchanged total volume of 0 shares throughout course of last trade however it holds an average trading capacity of 211.48 thousand shares.
The company is trading above its 50-day moving averages of 57.93 and up from 200-day moving averages of 60.91. The firm has price to book ratio of 1.60 and its price to sale ratio was 0.34.
According to ZACKS data, different Brokerage Firms rated the MGLN stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as BUY from 0 brokerage firms and recommended as Strong Buy by 1 brokerage firms.0 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 1 brokerage firms.3 brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of 3 based on consensus of the brokerage firms issuing ratings.
The average true range of Magellan Health, Inc.’s (MGLN) is recorded at 2.04 and the relative strength index of the stock stands 85.88. The stock price is going above to its 52 week low with 46.26% and lagging above from its 52 week high with 0.12%. Analyst recommendation for this stock stands at 2.80. A look on the firm performance, its monthly performance is 35.50% and a quarterly performance of 28.87%. The stock price is trading upbeat from its 200 days moving average with 16.25% and up from 50 days moving average with 28.58%.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) surged +0.59% and closed the trade at $ 13.66. The company recorded a trading capacity of 0 shares below its three months average daily volume of 999.2 thousand shares. The stock’s 50-day moving average is noted at $13.23 and its 200-day moving average is stands at $32.05.
Additionally, the company has EPS of -2.73. The company has market capitalization of $591.04M.
ITCI stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as Buy from 1 brokerage firms and 4 brokerage firms say as Strong Buy. 0 brokerage firms have suggested Sell for the company. 2 brokerage firms have recommended as a Hold. Strong Sell rating was given by 0 brokerage firms. The Company has average brokerage recommendation (ABR) of 1.71 based on consensus of the ZACKS brokerage firms.
Intra-Cellular Therapies, Inc.’s (ITCI) has price-to-cash ratio of 1.10 and price to sale ratio of 1970.23. A look on the firm performance, its monthly performance is 6.22% and a quarterly performance of -66.17%. The stock price is moving up from its 20 days moving average with 5.38% and isolated negatively from 50 days moving average with -29.25%.